Navigation Links
Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
Date:10/1/2013

London,UK (PRWEB) October 01, 2013

Targeting unmet needs in treating hematological malignances through the development of innovative drugs has witnessed considerable achievements recently. Over the past 10 years, proteasome inhibitor Velcade (Bortezomib) and the immunomodulatory drugs such as Revlimid (lenalidomide) and Thalomid (thalidomide) have become the basic treatments for multiple myeloma (MM) leading to the improvement in survival rates. Nevertheless, new treatment options for relapsed/refractory multiple myeloma (RRMM) are required to further improve survival and the quality of life of this group patients, and new drugs, such as Kyprolis (carfilzomib) or Pomalyst (pomalidomide, Imnovid), have already started to successfully fulfill this need.

The ever increasing need for innovative therapies for unmet needs/challenging diseases spurs the pace of drug development, either directly or through partnership/in-licensing. Meantime, maturing pipeline, successful launches and new drug approvals sustain the growth trajectory of the biotech companies.

In-demand research report “Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A” drawn up by MP Advisors has been recently published by Market Publishers Ltd.

Report Details:

Title: Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A
Published: September, 2013
Pages: 44
Price:    US$ 2,500.00
http://marketpublishers.com/report/diagnostics-diseases/cancer/treating-refractory-hematological-malignancies-multiple-myeloma-mm.html

The report offers an insightful overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM). It sheds light on the unmet needs and limitations of the current standard of care for relapsed and refractory MM patients. It describes the competitive scenario and delivers information on the leading biotech companies, covering clinical data of drugs, milestones, and valuation; indicates commercial opportunity in pursuing this therapy area. The research study reviews the early- and late-stage drugs in the clinic, covers key mergers and acquisitions in the area, provides clinical trial details of key drugs in pipeline, and offers an au-close look at the future of the drugs in the late-stage pipeline.

Report Scope:

  •     Comprehensive disease profile, review of unmet needs and description of the current standard of care.
  •     Extensive overview of the therapies for multiple myeloma (including newly diagnosed – NDMM and relapsed/refractory – RRMM).
  •     Data on the drugs in the pipeline: NDMM & RRMM – mechanism of action (MoA) and clinical stage of development.
  •     Clinical trial details of key drugs in pipeline.
  •     Discussion of the important issues related to the therapeutic area.
  •     Information on M&A and licensing deals that have taken place over the past five years.
  •     Evaluation of in-licensing and/or M&A opportunities.
  •     Insights into the competitive environment and detailed company profiles.
  •     Future outlook.

More new research reports by the publisher can be found at MP Advisors page.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11183653.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Today, the Whole-Food ... announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, ... Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 Aethlon ... Jim Joyce , Chairman and CEO, will be presenting at ... New York, NY at 2:15 p.m. ... participate in an Immunotherapy Panel discussion taking place at 3:15 ... available for replay approximately one hour after the conclusion of ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
Breaking Medicine Technology: